CAS: 134098-70-7; Fmoc-D-Asp-Otbu

相似化合物

77004-75-2 4125-93-3 34582-32-6

上下游产品

L-Aspartic acid 9-fluorenylmethyl N-succinimidyl carbonate isobutene (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)succinic acid 4-benzyl ester 1-tert-butyl esterα-fluorenylmethoxycarbonyl-L-aspartic acid α-tert-butyl-β-pentafluorophenyl esterNα-fluorenylmethoxycarbonyl-L-aspartic acid α-tert-butyl-β-pentafluorophenyl ester N-α-9-fluorenylmethoxycarbonyl-aspartic acid methyl-6-O-carboxy-(N-(9-fluorenylmethoxycarbonyl)-L-aspartic-acid α-tert-butyl ester)-2,3,4-tri-O-benzyl-α-D-manno-pyranoside methyl-6-O-carboxy-(N-(9-fluorenylmethoxycarbonyl)-L-aspartic-acid α-tert-butyl ester)-2,3,4-tri-O-4-methoxybenzyl-α-D-manno-pyranoside

9-芴甲基-N-琥珀酰亚胺基碳酸酯,(R)-Di-Tert-Butyl 2-Aminosuccinate置于copper(Ll) Sulfate Pentahydrate,Sodium Hydroxide,Edetate Disodium,Sodium Carbonate体系中,用 水,乙酸乙酯 用作溶剂,化学反应 3.0H,以72.3%的收率获得fmoc-D-天冬氨酸 1-叔丁酯
参考文献:一种n-9-芴甲氧羰基-D-天门冬氨酸-4-叔丁酯
标题:一种n-9-芴甲氧羰基-D-天门冬氨酸-4-叔丁酯
摘要:本发明公开了一种n‑9‑芴甲氧羰基‑d‑天门冬氨酸‑4‑叔丁酯的制备方法,(A)向反应容器中加入醋酸叔丁酯,滴加催化剂,加入d‑天门冬氨酸,于20‑50oc反应,浓缩处理,得d‑天冬门氨酸二叔丁酯;(B)将d‑天门冬氨酸二叔丁酯加入到硫酸铜溶液中,调节ph值至4‑8,得到d‑天冬门氨酸二叔丁酯铜盐水溶液;(C)向d‑天冬门氨酸二叔丁酯铜盐水溶液中依次加入有机溶剂和乙二胺四乙酸二钠,搅拌均匀,再向溶液体系中加入芴甲氧羰酰琥珀酰亚胺,调节ph值至3‑5,静置分层,萃取,干燥有机层,过滤,有机层加入石油醚,搅拌结晶,得到n‑9‑芴甲氧羰基‑d‑天门冬氨酸‑4‑叔丁酯.本发明的制备方法在生产过程中避免消旋,提高产品的光学纯度.

专利信息

专利号:US-5218089-A
优先权日:1988-12-23
标 题 :Retro-inverso analogues of thymopentin and the method for their synthesis
发明人：MARIOTTI SABINA; SISTO ALESSANDRO; NENCIONI LUCIANO; VILLA LUIGI; VERDINI ANTONIO S
权利人:SCLAVO SPA
摘要:New analogues of thymopentin (TP5) and of its tetrapeptide fragment (TP51-4) containing two non-contiguous retro-inverted bonds in the peptide chain are described which are of the general formula (I) (I) where R is hydrogen or an acyl radical, and R1 is an -OR2 group or an group where R2 is a hydrogen atom or a hydrocarbon radical, and R3 is a hydrogen atom or a hydroxyl group, and the corresponding pharmaceutically acceptable salts of acid or basic addition, possess immunomodulating activity.

专利号:US-8338565-B2
优先权日:2008-08-20
标 题 :Macrocyclic compounds for inhibition of tumor necrosis factor alpha
发明人：LEE JINBO; BOND JULIAN F; TERRETT NICHOLAS; FAVALORO JR FRANK G; WANG DANIEL; BRIGGS TIMOTHY F; SEIGAL BENJAMIN ADAM; SUN WEI-CHUAN; HALE STEPHEN P
权利人:LEE JINBO; BOND JULIAN F; TERRETT NICHOLAS; FAVALORO JR FRANK G; WANG DANIEL; BRIGGS TIMOTHY F; SEIGAL BENJAMIN ADAM; SUN WEI-CHUAN; HALE STEPHEN P; ENSEMBLE THERAPEUTICS CORP
摘要:Disclosed herein are macrocyclic compounds and methods for their synthesis and use. In particular, macrocyclic compounds are disclosed that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:EP-0375058-B1
优先权日:1988-12-23
标 题 :New retro-inverso analogues of trymopentin, the method for their synthesis and their use in the preparation of pharmaceutical compositions